ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Key Stats

• Today's Range: $4.38 to $4.63
• 50-Day Range: $3.53 to $4.99
• 52-Week Range: $3.34 to $5.82
• Volume: 24,463 shs
• Average Volume: 19,046 shs
• Market Capitalization: $39.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ICCC Stock Analysis - Frequently Asked Questions

How have ICCC shares performed this year?

ImmuCell's stock was trading at $5.09 at the start of the year. Since then, ICCC shares have decreased by 13.4% and is now trading at $4.41.
View the best growth stocks for 2024 here.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) issued its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.06) EPS for the quarter. The biotechnology company had revenue of $7.26 million for the quarter. ImmuCell had a negative net margin of 15.99% and a negative trailing twelve-month return on equity of 15.32%.

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 5/14/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ICCC
• CUSIP: N/A
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 75
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,780,000.00
• Net Margins: -15.99%
• Pretax Margin: -15.96%
• Return on Equity: -15.32%
• Return on Assets: -8.81%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 3.11
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $23.84 million
• Price / Sales: 1.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.23 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 8,912,000
• Free Float: 8,324,000
• Market Cap: $39.30 million
• Optionable: Not Optionable
• Beta: 0.60